semaglutide, Novo Nordisk

Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief executive of Ozempic maker Novo Nordisk warned Wednesday.
Novo Nordisk CEO warns of deaths linked to compounded semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.
Novo Nordisk will file semaglutide for MASH next year
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and European regulatory filings in the first half of next year.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues.
Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October requested the FDA block compounding pharmacies from producing versions of the drug, saying semaglutide is too complex for others to replicate safely.
Semaglutide Compounding Safety Concerns: 10 Deaths Reported
Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a medication linked to at least 10 deaths in the U.S. Learn more about the safety concerns.
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
FiercePharma6d
Novo Nordisk's semaglutide delivers in phase 3 MASH study, teeing up filings
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...
Outsourcing-pharma3d
Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...
FierceBiotech2d
Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail
Novo Nordisk, after mulling the implications of a phase 3 fail ... With ocedurenone gone, the only CKD program still ...
New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity
Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...
Pharmacists claim “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...